中国医药
中國醫藥
중국의약
CHINA MEDICINE
2014年
6期
799-801
,共3页
重组人脑利钠肽%难治性%心力衰竭
重組人腦利鈉肽%難治性%心力衰竭
중조인뇌리납태%난치성%심력쇠갈
Recombinant human brain natriuretic peptide%Refractory%Heart failure
目的 探讨冻干重组人脑利钠肽治疗难治性心力衰竭的临床效果.方法 选取31例难治性心力衰竭患者给予冻干重组人脑利钠肽治疗,首次负荷剂量1.5 μg/kg,静脉注射3～5min,随后按维持剂量0.007 5 ～0.01/(kg·min)进行微量泵注射72 h以上.观察治疗前后患者呼吸困难症状、24h尿量、心室率、左心室射血分数(LVEF)及N末端B型利钠肽前体(NT-proBNP)水平的变化情况.结果 重组人脑利钠肽给药结束24h时患者呼吸困难改善总有效率为90.3％(28/31);给药结束1周后患者NT-proBNP较治疗前明显下降[(5 042 ± 1 123) ng/L比(6 020±1 130) ng/L](P＜0.05),LVEF值较治疗前升高[(47 ± 15)％比(41 ± 15)％](P＜0.05),尿量较治疗前明显增加[(1 911±892)ml比(1 326 ± 802) ml](P＜0.05).结论 重组人脑利钠肽能明显改善难治性心力衰竭患者症状及心功能.
目的 探討凍榦重組人腦利鈉肽治療難治性心力衰竭的臨床效果.方法 選取31例難治性心力衰竭患者給予凍榦重組人腦利鈉肽治療,首次負荷劑量1.5 μg/kg,靜脈註射3～5min,隨後按維持劑量0.007 5 ～0.01/(kg·min)進行微量泵註射72 h以上.觀察治療前後患者呼吸睏難癥狀、24h尿量、心室率、左心室射血分數(LVEF)及N末耑B型利鈉肽前體(NT-proBNP)水平的變化情況.結果 重組人腦利鈉肽給藥結束24h時患者呼吸睏難改善總有效率為90.3％(28/31);給藥結束1週後患者NT-proBNP較治療前明顯下降[(5 042 ± 1 123) ng/L比(6 020±1 130) ng/L](P＜0.05),LVEF值較治療前升高[(47 ± 15)％比(41 ± 15)％](P＜0.05),尿量較治療前明顯增加[(1 911±892)ml比(1 326 ± 802) ml](P＜0.05).結論 重組人腦利鈉肽能明顯改善難治性心力衰竭患者癥狀及心功能.
목적 탐토동간중조인뇌리납태치료난치성심력쇠갈적림상효과.방법 선취31례난치성심력쇠갈환자급여동간중조인뇌리납태치료,수차부하제량1.5 μg/kg,정맥주사3～5min,수후안유지제량0.007 5 ～0.01/(kg·min)진행미량빙주사72 h이상.관찰치료전후환자호흡곤난증상、24h뇨량、심실솔、좌심실사혈분수(LVEF)급N말단B형리납태전체(NT-proBNP)수평적변화정황.결과 중조인뇌리납태급약결속24h시환자호흡곤난개선총유효솔위90.3％(28/31);급약결속1주후환자NT-proBNP교치료전명현하강[(5 042 ± 1 123) ng/L비(6 020±1 130) ng/L](P＜0.05),LVEF치교치료전승고[(47 ± 15)％비(41 ± 15)％](P＜0.05),뇨량교치료전명현증가[(1 911±892)ml비(1 326 ± 802) ml](P＜0.05).결론 중조인뇌리납태능명현개선난치성심력쇠갈환자증상급심공능.
Objective To investigate the clinical effects of lyophilized recombinant human brain natriuretic peptide on refractory heart failure.Methods Totally 31 cases of refractory heart failure patients were treated with lyophilized recombinant human brain natriuretic peptide.The first loading dose of 1.5 μg/kg was intravenous in 3-5 min,followed by a maintenance dose of 0.007 5-0.01/(kg · min) conduct micro pump injection of at least 72 h.Symptom of breath,24 h urine output,heart rate,left ventricular ejection fraction (LVEF) and N-terminal B-type natriuretic peptide precursor (NT-proBNP) levels was evaluated and measured before and after treatment.Results After 24 hours of recombinant human brain natriuretic peptide therapy,total response rate of dyspnea grade improvement was 90.3％ (28/31).NT-proBNP one week after treatment was decreased slightly compared with before treatment[(5 042 ± 1 123) ng/L vs (6 020 ± 1 130) ng/L] (P ＜ 0.05) ; LVEF values increased [(47±15)％ vs (41 ±15)％] (P＜0.05); urine output increased[(1 911 ±892)ml vs (1 326±802)ml] (P ＜0.05).Conclusion The recombinant human brain natriuretic peptide can significantly improve cardiac function and clinical symptoms in patients with refractory heart failure.
